3 272

Cited 13 times in

Statin Therapy Is Associated With the Development of New-Onset Diabetes After Transplantation in Liver Recipients With High Fasting Plasma Glucose Levels

 Yongin Cho  ;  Min Jung Lee  ;  Eun Yeong Choe  ;  Chang Hee Jung  ;  Dong Jin Joo  ;  Myoung Soo Kim  ;  Bong Soo Cha  ;  Joong-Yeol Park  ;  Eun Seok Kang 
 LIVER TRANSPLANTATION, Vol.20(5) : 557-563, 2014 
Journal Title
Issue Date
Adult ; Aged ; Allografts ; Blood Glucose/analysis* ; Diabetes Mellitus/etiology* ; Diabetes Mellitus/prevention & control* ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects* ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use* ; Liver Failure/complications ; Liver Failure/surgery* ; Liver Transplantation* ; Longitudinal Studies ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
New-onset diabetes after transplantation (NODAT) and dyslipidemia are important metabolic complications after liver transplantation (LT) that can adversely affect both allograft and patient survival. Statins are used as first-line therapies for dyslipidemia because of their effectiveness and safety profile. However, it has recently been reported that statin therapy is associated with new-onset diabetes in the nontransplant population. The aim of this study was to investigate the association between statin therapy and the development of NODAT in LT recipients. Three hundred sixty-four LT recipients who underwent transplantation between the ages of 20 and 75 years without a previous history of diabetes were enrolled in this study. We evaluated the incidence of NODAT with respect to statin use as well as other risk factors. The incidence of NODAT was significantly higher in the statin group (31.7%) versus the control group (17.6%, P = 0.03). The mean follow-up period was 37.8 ± 19.0 months for the statin group and 42.7 ± 16.0 months for the control group (P = 0.07). Statin use was significantly associated with NODAT development after adjustments for other risk factors [hazard ratio (HR) = 2.32, 95% confidence interval (CI) = 1.23-4.39, P = 0.01]. Impaired fasting glucose before transplantation was also a risk factor for NODAT development (HR = 2.21, 95% CI = 1.36-3.62, P = 0.001). There were no significant differences in age, body mass index, cumulative corticosteroid dose, or fasting plasma glucose (FPG) levels between the groups. Patients with high FPG levels were more likely to develop NODAT when they were placed on statins after LT (P = 0.002). In conclusion, statin treatment could contribute to the development of NODAT in LT recipients, especially if they have high baseline FPG levels.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Kim, Myoung Soo(김명수) ORCID logo https://orcid.org/0000-0002-8975-8381
Cho, Yong In(조용인) ORCID logo https://orcid.org/0000-0002-4645-816X
Joo, Dong Jin(주동진) ORCID logo https://orcid.org/0000-0001-8405-1531
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
Choe, Eun Yeong(최은영)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.